New oral anticoagulants in the ED setting: A review

American Journal of Emergency Medicine

Volumn 30, Issue 9, 2012, Pages 2046-2054

  Pollack, Charles V ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; THROMBIN INHIBITOR; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EMBOLISM; EMERGENCY PHYSICIAN; EMERGENCY WARD; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; LONG TERM CARE; MEDICAL DECISION MAKING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; THROMBOSIS PREVENTION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

EID: 84869183192     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2012.04.005     Document Type: Review

References (47)

1. C.J. Anthony, S. Karim, and S. Ackroyd-Stolarz Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department Ann Pharmacother 45 2011 881 887
2. D.S. Budnitz, M.C. Lovegrove, N. Shehab, and C.L. Richards Emergency hospitalizations for adverse drug events in older Americans N Engl J Med 365 2011 2002 2012
3. Lovenox (package insert) 2011 Sanofi-aventis Bridgewater, NJ
4. Pradaxa [package insert] 2011 Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT
5. Xarelto [package insert] 2011 Janssen Pharmaceuticals, Inc. Titusville, NJ
6. Eliquis [summary of product characteristics] 2011 Bristol-Myers Squibb/Pfizer EEIG Middlesex, UK
7. V. Snow, A. Qaseem, and P. Barry Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians Ann Intern Med 146 2007 204 210
8. C. Kearon, E.A. Aki, and A.J. Comerota Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (9th edition) Chest 141 Suppl 2012 e419S e494S
9. S. Schulman, C. Kearon, and A.K. Kakkar Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
10. S. Schulman, D. Baanstra, and H. Eriksson Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism Presented at: ISTH 2011;Kyoto, Japan:July 25-28 2011 Abstract O-MO-037. http://www.isth2011.com/ prgrm-common/abstracts/html/03103.html
11. S. Schulman, H. Eriksson, and S.Z. Goldhaber Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism Abstract O-TH-033 Presented at: ISTH 2011;Kyoto, Japan:July 25-28 2011 http://www.isth2011.com/ prgrm-common/abstracts/html/02116.html
12. R. Bauersachs, S.D. Berkowitz, and B. Brenner Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
13. H.R. Buller, M.H. Prins, and A.W.A. Lensing Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297 http://www.nejm.org/toc/nejm/366/14/
14. H. Buller, D. Deitchman, M. Prins, and A. Segers Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study J Thromb Haemost 6 2008 1313 1318
15. Bristol-Myers Squibb. ClinicalTrials.gov ID: NCT00643201. Efficacy and safety study of apixaban for the treatment of deep vein thrombosis or pulmonary embolism. http://www.clinicaltrials.gov/ct2/show/NCT00643201?term= apixaban&rank=7.
16. A.J. Camm, P. Kirchhof, and G.Y. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
17. A.S. Go, E.M. Hylek, and K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study JAMA 285 2001 2370 2375
18. R.K. Sandhu, J.A. Bakal, J.A. Ezekowitz, and F.A. McAlister The epidemiology of atrial fibrillation in adults depends on locale of diagnosis Am Heart J 161 2011 986 992
19. A.J. McDonald, A.J. Pelletier, P.T. Ellinor, and C.A. Camargo Jr. Increasing US emergency department visit rates and subsequent hospital admissions for atrial fibrillation from 1993 to 2004 Ann Emerg Med 51 2008 58 65
20. D.E. Singer, G.W. Albers, and J.E. Dalen Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 133 Suppl 2008 546S 592S
21. V. Fuster, L.E. Ryden, and D.S. Cannom 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 2011 e269 e367
22. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
23. The Atrial Fibrillation Investigators The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials Arch Intern Med 157 1997 1237 1240
24. L.S. Wann, A.B. Curtis, and K.A. Ellenbogen 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines J Am Coll Cardiol 57 2011 1330 1337
25. J.J. You, D.E. Singer, and P.A. Howeard Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th edition; American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 Suppl. 2012 e531S e575S
26. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
27. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
28. S.J. Connolly, J. Eikelboom, and C. Joyner Apixaban in patients with atrial fibrillation N Engl J Med 363 2011 806 817
29. C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
30. R.S. Wright, J.L. Anderson, and C.D. Adams 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J Am Coll Cardiol 57 2011 1920 1959
31. P.A. Merlini, K.A. Bauer, and L. Oltrona Persistent activation of coagulation mechanism in unstable angina and myocardial infarction Circulation 90 1994 61 68
32. M.B. Rothberg, C. Celestin, L.D. Fiore, E. Lawler, and J.R. Cook Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit Ann Intern Med 143 2005 241 250
33. L. Wallentin, R.G. Wilcox, and W.D. Weaver Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797
34. J. Oldgren, A. Budaj, and C.B. Granger Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 2781 2789 [Epub 2011 May 7.]
35. J.L. Mega, E. Braunwald, and S. Mohanavelu Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 2009 29 38
36. J.L. Mega, E. Braunwald, and S.D. Wiviott Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19 http://www.nejm.org/ toc/nejm/366/1
37. J.H. Alexander, R.C. Becker, and D.L. Bhatt Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial Circulation 119 2009 2877 2885
38. J.H. Alexander, R.D. Lopes, and S. James Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708 [Epub 2011 Jul 24.]
39. J. Stangier, K. Rathgen, and H. Stahle The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303 10.1111/j.1365-2125.2007.02899.x [Epub 2007 May 15.]
40. M.M. Samama, G. Contant, and T.E. Spiro Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls Thromb Haemost 2011 107 [epub ahead of print]
41. R.C. Becker, H. Yang, and Y. Barrett Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban - an oral, direct and selective factor Xa inhibitor J Thromb Thrombolysis 32 2011 183 187
42. J. van Ryn, J. Stangier, and S. Haertter Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
43. Perzborn E, Harwardt M. Recombinant factor VIIa partially reverses the effects of the factor Xa inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro. Presented at: XXIst Congress of the International Society on Thrombosis and Haemostasis; Geneva, Switzerland: July 6-12, 2007. Abstract P-W-640. J Thromb Haemost 2007;5(suppl. 2):P-W-640.
44. Tinel H, Huetter J, Perzborn E. Recombinant factor VIIa partially reverses the anticoagulant effect of high-dose rivaroxaban - a novel, oral factor Xa inhibitor - in rats. Presented at: XXIst Congress of the International Society on Thrombosis and Haemostasis; Geneva, Switzerland: July 6-12, 2007. J Thromb Haemost. 2007;5(suppl. 2):P-W-652.
45. Lu G, DeGuzman F, Karbarz MJ, et al. Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote, PRT064445). Presented at: European Society of Cardiology (ESC) Congress 2011; Paris, France: Aug 27-31, 2011. Abstract 3715. Eur Heart J 2011;32 (abstract supplement):640-41.
46. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
47. S.T. Garber, W. Sivakumar, and R.H. Schmidt Neurosurgical complications of direct thrombin inhibitors - catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran J Neurosurg 2012 e-pub ahead of print]